Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Zhonghua Wei Chang Wai Ke Za Zhi = Chinese Journal of Gastrointestinal Surgery|June 24, 2014
[Clinical significance of the detection of serum neutrophil gelatinase-associated lipocalin in human colorectal cancer]Lei Ding, Xiufeng Zhang, Yanxiang Zhang, et al.
Experimental Cell Research|January 3, 2022
Integrin αvβ6 contributes to the development of intestinal fibrosis via the FAK/AKT signaling pathwayHaiting Xie, Yurong Jiao, Xinbin Zhou, et al.
The British Journal of Nutrition|February 27, 2026
Effect of Modified Mediterranean Diet Supplemented with Partial Enteral Nutrition in Post-surgical Patients with Crohn's Disease: A Pilot Clinical TrialXiaoxu Huang, Yan Chen, Zhifang Zhong, et al.
Inflammatory Bowel Diseases|February 3, 2024
Monitoring-Based Model for Personalizing Fecal Incontinence in Patients With Crohn's Disease: A Multicenter Inception Cohort StudyCan Wang, Fan Yang, Lichao Qiao, et al.
BMC Cancer|July 18, 2023
Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric studyXuefeng Fang, Chenhan Zhong, Shanshan Weng, et al.
Inflammatory Bowel Diseases|November 29, 2025
Efficacy of Consistency Versus Switching of Biologics for Prevention of Postoperative Recurrence in Crohn's Disease: A Multicenter Real-World Retrospective StudyChunjie Zhang, Juan Wu, Zhaoxiu Liu, et al.
BMC Medicine|May 5, 2022
Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapyYue Liu, Qian Xiao, Jinjie He, et al.
Eclinicalmedicine|August 9, 2023
Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trialXuefeng Fang, Ning Zhu, Chenhan Zhong, et al.
Pageof 2